









Humber Area Prescribing Committee

Summary of decisions made regarding new product requests considered at a meeting of the Committee on August 2023

Classification of products:

Status	Description
 GREEN	Medicines suitable for routine use within primary care and Secondary care. May be initiated within primary care within their licensed indication, in accordance with nationally recognised formularies
 AMB 1	Specialist recommendation: These medicines are considered suitable for GP prescribing following specialist recommendation or via an APC approved prescribing guideline.
 AMB 2	Specialist initiation: These medicines are considered suitable for GP prescribing following specialist initiation, including titration of dose and assessment of efficacy. These medicines may also have an APC approved guideline to aid GPs in further prescribing.
 AMB SCP	AMBER SHARE CARE PROTOCOL- Specialist initiation with ongoing monitoring: Medicines that must be initiated by a specialist, and which require significant monitoring on an ongoing basis. Full agreement to share the care of each specific patient must be reached under the shared care protocol which must be provided to the GP. If a commissioned shared care is not available in CCG/place then these drugs must be treated as red drug (hospital only).
 RED	Red-Hospital initiation and continuation only
 GREY	GREY- NON FORMULARY (As agreed by Area Prescribing Committee)
 PURPLE	To be supplied from the appropriate commissioned provider.
 NR	Not routinely commissioned

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
1) Requests deferred from previous meetings				
Nil this month				
2) New Requests				
Avacopan	RED			TA825 - HUTH
Avatrombopag	RED			TA853 - HUTH
3) New formulations & extensions to use				
Nil this month				

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
4) Products considered by NICE				
TA893: Brexucabtagene autoleucl for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over	RED			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA895: Axicabtagene ciloleucl for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy	RED			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA896: Bulevirtide for treating chronic hepatitis D	RED			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA897: Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma	RED			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA898: Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer	RED			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA903: Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer	RED			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA904: Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer	RED			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA907: Deucravacitinib for treating moderate to severe plaque psoriasis	RED			The formulary will reflect the TAG – ICS is the responsible commissioner.
TA894: Axicabtagene ciloleucl for treating relapsed or refractory follicular lymphoma	NR			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA899: Esketamine for treating major depressive disorder in adults at imminent risk of suicide (terminated appraisal)				The formulary will reflect the TAG – ICS is the responsible commissioner. Received for information.

DECISION SUMMARY

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
TA900: Tixagevimab plus cilgavimab for preventing COVID-19	NR			The formulary will reflect the TAG – ICS is the responsible commissioner.
TA902: Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction	AMB 1			The formulary will reflect the TAG – ICS is the responsible commissioner.
5) Appeals against earlier decisions by the APC				
None				
6) Miscellaneous formulary decisions by the APC				
Nil this month				

The following guidelines were presented to and approved at the August 2023 meeting of the APC:

- Oral Paracetamol

The following Drug information leaflets were presented to and approved at the August 2023 meeting of the APC:

- Sick Day Guidance in T2DM

The following shared care guidelines were presented to and approved at the August 2023 meeting of the APC:

- Amiodarone SCF

Other documents presented to and approved at the August 2023 meeting of the APC:

- ICB Type 2 diabetes (for info only)
- ICB CGM policy (for information only)